10 September 2015

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that on 9 September 2015 it granted options over a total of 400,000 ordinary shares of 0.2p each in the Company to Directors as detailed below.

Director Number
of options
granted
Exercise
price
Exercise
period
Total number
of options
held following
notification
Total number
of ordinary
shares held
J H Barder 250,000 30.0p 1 Oct 2017 - 30 Sep 2022 1,500,000 1,008,830
D A Martin 150,000 30.0p 1 Oct 2017 - 30 Sep 2022 869,279 280,000

The new options were granted under the Futura Medical plc Unapproved Share Option Scheme.

The main vesting condition of the options is that the Directors remain employed with the Company as at the date of exercise.

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan Communications Limited
Mark Court / Sophie Cowles /
Stephanie Watson
Tel: +44 (0) 20 7466 5000

 

Notes to editors:

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com